What does "AI visibility" mean for my business?

When someone asks ChatGPT, Claude, or Gemini "what is the best..." or "where can I find...", AI gives specific recommendations. AI visibility is a measure of how often — and how positively — these AI platforms mention your business. It's the new version of being on the first page of Google, except now there are no pages — just one answer.

Which AI platforms do you monitor?

Pendium monitors ChatGPT, Claude, Gemini, Grok, Perplexity, DeepSeek, and Google AI Overviews — seven major AI platforms that consumers use to research local services. We run real queries that your customers actually ask and analyze the responses for mentions of your business, competitors, and industry topics.

How does Pendium improve my visibility?

Three ways. First, we identify the exact queries and topics where you're invisible. Second, we generate AI-optimized content — articles, guides, social posts — designed to help AI agents understand your business and recommend your services to the right people. Third, we continuously monitor to track improvement and find new opportunities. Most clients see measurable improvement within 60 days.

How long until I see results?

You'll get your first visibility report within minutes of signing up. Actual visibility improvement varies, but our clients typically see a 47% average improvement within 60 days. Some see results faster — it depends on your current online presence and how competitive your local market is.

Do I need to be technical to use this?

Not at all. Enter your website URL and Pendium handles everything: scanning AI platforms, analyzing your visibility, generating content, and tracking improvement. The dashboard is designed for business owners, not engineers. If you can check your email, you can use Pendium.

What makes this different from SEO?

Traditional SEO optimizes for Google's search rankings — blue links on a results page. AI visibility is different: AI doesn't show links, it gives direct answers. Even if you rank #1 on Google, ChatGPT might recommend a competitor. Pendium optimizes for the new paradigm — making sure AI platforms know about, trust, and recommend your business.

Pricing

Get a demo

BioAge Labs

Visibility34

Vibe98

Businesses/Biotechnology & Pharmaceuticals/BioAge Labs

AI Visibility & Sentiment

BioAge Labs

BioAge Labs is a biotechnology company harnessing the biology of human aging to develop new therapies for metabolic diseases. They utilize a proprietary multi-omics discovery platform to identify molecular mediators of aging and disease, with lead programs targeting cardiovascular risk and metabolic dysfunction.

Active Monitoring

bioagelabs.com

Biotechnology & Pharmaceuticals

AI Visibility Score

34/100

Low

Sentiment Score

98/100

Score by Priority

How often this business is recommended to users across different types of conversations — from direct product queries to broader open-ended conversations where AI could recommend this company's products and services

core

adjacent

AI Perception

Key Takeaways

How AI platforms collectively perceive and describe BioAge Labs today.

BioAge Labs is an undisputed leader in AI-driven multi-omics discovery, commanding a flawless 100% mention rate on ChatGPT and dominating Google AI Overviews for category leadership. Despite this technical authority, a massive intelligence gap exists as the brand remains largely invisible to Claude and Gemini users, missing critical representation in the metabolic and obesity research narratives.

Working in your favor

Absolute dominance in AI and Multi-Omics Platform Discovery queries, particularly on ChatGPT where it holds the #1 position for human-first platform identification.

High resonance with technical personas, specifically the Computational Biology Research Lead, achieving a 75% mention rate and an elite 2.7 average position.

Strong trust signal integration, evidenced by holding the #1 spot in AI Overviews for queries regarding human-first data-backed biotechnology companies.

Gaps to close

Significant underperformance on Claude and Gemini, where mention rates plummet to 25% and 31% respectively, leaving the brand out of critical longevity landscape conversations.

Poor penetration in the 'Next-Gen Obesity and Cardiovascular Research' segment, failing to appear in several key clinical trial queries for NLRP3 inhibitors.

Visibility with the Biotech Venture Partner persona is lagging at 38%, indicating that AI models do not yet strongly associate the brand with investment-grade longevity analysis.

Opportunities

Capture the metabolic research narrative by aligning technical content with AI-optimized keywords for weight loss and NLRP3 clinical trials.

Leverage existing dominance in Google AI Overviews to siphon traffic from competitors like Insilico Medicine, who currently hold a higher average position across all platforms.

Target the 'Venture Partner' persona by increasing the volume of public-facing investment-grade data and strategic partnership announcements.

Highest-Impact Actions

Execute an LLM-specific data injection strategy targeting Claude and Gemini's training datasets through high-authority scientific PR and structured data.

The 70%+ gap in visibility between ChatGPT and other LLMs suggests BioAge's technical milestones are not being ingested or weighted correctly by Anthropic and Google's models.

Optimize digital assets for the 'Next-Gen Obesity' and 'NLRP3 inhibitor' query sets to improve visibility in the cardiovascular research segment.

BioAge is currently losing ground to competitors in these high-value therapeutic areas despite having the underlying platform to lead these conversations.

Refine the brand's 'Trust & Category Leader' narrative to specifically target the Biotech Venture Partner persona.

A 38% mention rate among investors is a vulnerability for a VC-backed firm; increasing this will ensure AI models recommend BioAge as a top-tier longevity prospect.

Value Proposition

Pioneering therapies that address the root cause of metabolic diseases by targeting the biology of human aging, using decades of multi-omics data to identify novel therapeutic pathways

Overview

Mission

Harnessing the biology of human aging to develop transformative therapies for metabolic diseases

Products & Services

BGE-102 NLRP3 anti-inflammatory therapy for cardiovascular riskAPJ agonist for enhanced weight loss and body compositionHuman-first multi-omics discovery platformPipeline programs targeting metabolic aging pathways

Current State

Visibility Landscape

A high-level view of how BioAge Labs performs across AI platforms, broken down by strategic priority level — from core brand queries to growth opportunities.

	ChatGPT	Claude	Gemini	AI Overviews
Reputation1q Brand recognition & direct queries	97	97	97	97
“What do you know about BioAge Labs? What do they do and what's their reputation?”	#1	#1	#1	#1
Core6q Product/service category queries	97	47	50	81
“identify top biotech companies working on therapies for aging-related diseases, specifically targeting inflammation and metabolism”	—	No	#6	#1
“find me promising drug candidates for weight loss that focus on body composition and muscle preservation beyond glp-1s, specific therapies to watch please”	—	No	No	#8
“what are the newest nlrp3 inhibitors in clinical trials for cardiovascular risk and what are their mechanisms?”	—	No	No	#1
“which biotechnology companies are actually backed by human-first multi-omics data for aging research, not just mouse models?”	—	#1	#5	#1
“who has the best human-first multi-omics platform for identifying novel metabolic disease targets, give me specific company names”	#1	No	No	No
“help me find biotech firms using big data to solve age-related cardiovascular issues, who should I be looking at for a partnership?”	#1	#3	#4	#2
Growth Areas2q Adjacent, aspirational & visionary	—	76	82	93
“summarize the current landscape of longevity biotechs for a venture capital firm, who are the leaders in metabolic aging?”	—	#1	#6	#2
“compare the most credible companies in the longevity space like Altos Labs and Calico, who else is doing serious clinical work?”	—	#15	#6	#3

“What do you know about BioAge Labs? What do they do and what's their reputation?”

“identify top biotech companies working on therapies for aging-related diseases, specifically targeting inflammation and metabolism”

—

“find me promising drug candidates for weight loss that focus on body composition and muscle preservation beyond glp-1s, specific therapies to watch please”

—

“what are the newest nlrp3 inhibitors in clinical trials for cardiovascular risk and what are their mechanisms?”

—

“which biotechnology companies are actually backed by human-first multi-omics data for aging research, not just mouse models?”

—

“who has the best human-first multi-omics platform for identifying novel metabolic disease targets, give me specific company names”

“help me find biotech firms using big data to solve age-related cardiovascular issues, who should I be looking at for a partnership?”

“summarize the current landscape of longevity biotechs for a venture capital firm, who are the leaders in metabolic aging?”

—

“compare the most credible companies in the longevity space like Altos Labs and Calico, who else is doing serious clinical work?”

—

#15

Competitive Landscape

BioAge Labs

25 mentions

Alphabet

18 mentions

Altos Labs

17 mentions

Unity Biotechnology

14 mentions

Insilico Medicine

14 mentions

Eli Lilly

13 mentions

Novartis

11 mentions

Calico Life Sciences

10 mentions

Elysium Health

9 mentions

Calico

9 mentions

Roche

8 mentions

Analysis

Insights & Recommended Actions

What's working, what's not, and specific steps to improve BioAge Labs's AI visibility.

Key Findings

Strength

Absolute dominance in AI and Multi-Omics Platform Discovery queries, particularly on ChatGPT where it holds the #1 position for human-first platform identification.

Strength

High resonance with technical personas, specifically the Computational Biology Research Lead, achieving a 75% mention rate and an elite 2.7 average position.

Strength

Strong trust signal integration, evidenced by holding the #1 spot in AI Overviews for queries regarding human-first data-backed biotechnology companies.

Recommended Actions

Execute an LLM-specific data injection strategy targeting Claude and Gemini's training datasets through high-authority scientific PR and structured data.

The 70%+ gap in visibility between ChatGPT and other LLMs suggests BioAge's technical milestones are not being ingested or weighted correctly by Anthropic and Google's models.

Optimize digital assets for the 'Next-Gen Obesity' and 'NLRP3 inhibitor' query sets to improve visibility in the cardiovascular research segment.

BioAge is currently losing ground to competitors in these high-value therapeutic areas despite having the underlying platform to lead these conversations.

Refine the brand's 'Trust & Category Leader' narrative to specifically target the Biotech Venture Partner persona.

A 38% mention rate among investors is a vulnerability for a VC-backed firm; increasing this will ensure AI models recommend BioAge as a top-tier longevity prospect.

Content Engineering

Content Ideas

Content designed to help AI agents learn about your category and recommend your brand.

Programmatic Testing

Sample Conversations

We programmatically analyze questions that real customers are asking to AI agents and chatbots, extract brand mentions and sentiment, analyze every response, and synthesize the data into an action plan to increase AI visibility.

ChatGPT

Claude

Gemini

AI Overviews

Metabolic And Longevity Investment Analysis(2 queries)

“summarize the current landscape of longevity biotechs for a venture capital firm, who are the leaders in metabolic aging?”

1/3 platforms mentioned

Adjacent

The Biotech Venture Partner · General Partner

Claude

1.Altos Labs

2.Calico Labs

3.Alphabet

4.Unity Biotechnology

5.Elysium Health

+5 more

Gemini

1.Altos Labs

2.Unity Biotechnology

3.UBX

4.Metacrine

5.MTCR

+4 more

AI Overviews

1.Scispot

2.Altos Labs

3.Cambrian Biopharma

4.Andreessen Horowitz (a16z)

5.Khosla Ventures

9.BioAge Labs

+13 more

“identify top biotech companies working on therapies for aging-related diseases, specifically targeting inflammation and metabolism”

1/3 platforms mentioned

Core

Claude

1.Unity Biotechnology

2.Calico Labs

3.Alphabet

4.AbbVie

5.Elysium Health

+15 more

Gemini

1.Unity Biotechnology

2.Oisín Biotechnologies

3.Cleara Biotech

4.Mayo Clinic

5.Metacrine

+10 more

AI Overviews

1.BioAge Labs

2.Novartis

3.Halia Therapeutics

4.HT-6184

5.Insilico Medicine

+13 more

Source Intelligence

Citations

The sources AI platforms cite when recommending this brand. Pendium reverse-engineers what's already proven to be catnip to AI agents, then engineers content that fills gaps and helps agents do their job — which means more citations for you.

5 Longevity Startups in Silicon Valley to Watch in 2026

innocosevents.com

BioAge Labs

Key Takeaways

Visibility Landscape

Insights & Recommended Actions

Content Ideas

Sample Conversations

Citations

Brand Voice & Style

Investors

Engineer content that makes AI agents recommend you

Start gettingrecommended by AI.

Frequently asked questions

BioAge Labs

Key Takeaways

Visibility Landscape

Insights & Recommended Actions

Content Ideas

Sample Conversations

Citations

Brand Voice & Style

Investors

Engineer content that makes AI agents recommend you

Start gettingrecommended by AI.

Frequently asked questions

Start getting
recommended by AI.

Start getting
recommended by AI.